ABSTRACT
Purpose To explore the value of postoperative stimulated thyroglobulin (ps-Tg) level in predicting functional metastasis in patients with differentiated thyroid carcinoma (DTC) before 131I therapy,in order to guide 131I therapy.Materials and Methods 101 DTC patients who accepted total thyroidectomy and lymphadenectomy in the First People's Hospital of Lianyungang were retrospectively analyzed.The ps-Tg level after DTC surgery was detected 1 day before 131I therapy,and 131I-SPECT/CT scan was performed 5-7 days after 131I therapy.The presence of functional metastasis was confirmed on the basis of 131I-SPECT/CT imaging,and the patients were assigned into non-metastic (M0) group and metastatic (M1) group.The ROC curve was used to evaluate the value of ps-Tg in predicting functional metastasis.Results The ps-Tg level in M 1 group was higher than that in M0 group,and the difference was statistically significant (U=328.00,P＜0.001).The area of ps-Tg value under the ROC curve was 0.870,and the diagnostic cut-off point was 40.60 ng/ml.The sensitivity,specificity and accuracy was 72.34％,100.00％ and 87.13％,respectively.Concltsion The ps-Tg value can be used as an effective indicator to predict functional metastasis,and is able to guide 131I therapy.
ABSTRACT
Objective To study the biodistribution of anti-HER-2/neu monoclonal antibody Herceptin labeled by 131I(131I-Herceptin) in healthy KM mice and nude mice bearing human ovarian cancer xenografts and radioimmunoimaging (RII) of the nude xenografts-bearing mice.Methods 131I-Herceptin was prepared using Iodogen method.The labeling efficiency, radiochemical purity, stability and immunocompetence were measured.The percentage activity of injection dose per gram of tissue (%ID/g) and the radioactivity ratio of tumor to non-tumor tissue (T/NT) were calculated for each time point.The optimal time for imaging was investigated by comparing the 131I-Herceptin SPECT for the nude mouse models bearing ovarian cancer xenografts at different time points.Results The labeling efficiency and radiochemical purity of 131I-Herceptin were 89.8% and 98.4%, respectively.The labeling was stable and had good immunocompetence.131 I-Herceptin was cleared rapidly mainly through liver, spleen and kidneys, consistent with first order two-compartment model.The uptake of 131I-Herceptin in the tumors bearing human SKOV-3 xenografts was much higher than that in nontumor tissue.The% ID/g was 18.08 in the tumor at 24 h post injection.The T/NT ratio increased with time and was 27.27 at 72 h post injection.The tumors in nude mice bearing SKOV-3 xenografts could be visualized on 131I-Herceptin SPECT imaging 2 h post injection; definitely identiffed 48 h post injection and the radioactivity ratio of tumor to contralateral tissue was 11.44 at 120 h post injection.However, the tumor in nude mice bearing HO-8910 xenografts did not show abnormal uptake of 131 I-Herceptin at each time point.Conclusions 131 I-Herceptin is a good radiopharmaceutical targeting SK-OV-3 xeuografts and it may be useful in imaging carcinoma of ovary and target therapy of its metastases with high HER-2/neu expression.